Vasiliki Leventaki

Vasiliki Leventaki

Auto-generated profile, based on publicly available information

Vasiliki Leventaki

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao
We herein present an overview of the upcoming 5thedition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4thedition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5thedition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

10 November 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
WCWeina Chen
Weina Chen
EDElias Drakos
Elias Drakos
IGIoannis Grammatikakis
Ioannis Grammatikakis
ESEllen J Schlette
Ellen J Schlette
JLJiang Li
Jiang Li
GRGeorge Z Rassidakis
George Z Rassidakis
Activating mutations of the FLT3 gene mediate leukemogenesis, at least in part, through activation of PI3K/AKT. The mammalian target of rapamycin (mTOR)-Raptor signaling pathway is known to act downstream of AKT. Here we show that the mTOR effectors, 4EBP1, p70S6K and rpS6, are highly activated in cultured and primary FLT3-mutated acute myeloid leukemia (AML) cells. Introduction of FLT3-ITD expressing constitutively activated FLT3 kinase further activates mTOR and its downstream effectors in BaF3 cells. We also found that mTOR signaling contributes to tumor cell survival, as demonstrated by pharmacologic inhibition of PI3K/AKT/mTOR, or total silencing of the mTOR gene. Furthermore, inhibition of FLT3 kinase results in downregulation of mTOR signaling associated with decreased survival of FLT3-mutated AML cells. These findings suggest that mTOR signaling operates downstream of activated FLT3 kinase thus contributing to tumor cell survival, and may represent a promising therapeutic target for AML patients with mutated-FLT3.

19 July 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao

1 April 2003 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
HAHesham M. Amin
Hesham M. Amin
TMTimothy J McDonnell
Timothy J McDonnell
LML Jeffrey Medeiros
L Jeffrey Medeiros
GRGeorgios Z Rassidakis
Georgios Z Rassidakis
VLVasiliki Leventaki
Vasiliki Leventaki
RLRaymond Lai
Raymond Lai
Mantle cell lymphoma (MCL) is a distinct type of B-cell non-Hodgkin lymphoma characterized by t(11;14)(q13;q32) and cyclin D1 overexpression. The pathogenesis of MCL has not been comprehensively studied, which can be attributed in part to the paucity of well-characterized MCL cell lines. We collected 4 previously developed MCL cell lines and performed extensive characterization, including the susceptibly of these cell lines to transduction by adenovirus vectors. Our aim was to facilitate the establishment of an in vitro model that can be reliably used to study the pathogenesis of MCL. Standard techniques were used to compare the morphologic, immunophenotypic, and cytogenetic features of the 4 cell lines. In addition, Western blotting was used to investigate the presence of several cell cycle- and apoptosis-related proteins. TP53 DNA sequencing was also performed on the cell lines. The adenoviral transduction efficiency was assessed using an adenoviral vector carrying the gene encoding for the green fluorescence protein (Ad-GFP). All cell lines demonstrated evidence of t(11;14)(q13;q32) and overexpression of cyclin D1. Cyclin D2 was not detectable in all cell lines, whereas cyclin D3 was weakly expressed in JeKo-1 and SP-53. Other abnormalities of the cell cycle G1 phase regulatory pathway were detected, including loss of expression of p53 (JeKo-1) and p16(INK4a) (SP-53 and Granta 519), as well as TP53 mutation (Mino). All cell lines express high levels of cyclin E, c-Myc, Bcl-2, Bax, Bcl-x(L), and Mcl-1. Retinoblastoma protein is hyperphosphorylated in all cell lines. With the exception of Mino, MCL cell lines are highly transducible with adenoviral vectors. These cell lines are representative of MCL and can be used as an in vitro model to further explore the pathogenesis of this disease. The susceptibility of these cell lines to gene transfer provides opportunities to evaluate the importance of various oncogenes and tumor suppressor genes that may have an impact on developing effective therapeutic regimens for MCL.

15 August 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
YPYunbao Pan
Yunbao Pan
SWSumei Wang
Sumei Wang
BSB Su
B Su
FZFuling Zhou
Fuling Zhou
RZR Zhang
R Zhang
FCFrancois-xavier Claret
Francois-xavier Claret
Our previous studies demonstrated that Jab1/Csn5 overexpression is correlated with low survival rates in cancer patients, including nasopharyngeal carcinoma (NPC), breast cancer and hepatocellular carcinoma, and contributes to NPC’s resistance to radiotherapy and cisplatin by regulating DNA damage and repair pathways. However, the molecular mechanism by which Jab1/Csn5 expression is upregulated in NPCs has yet to be determined. In the present study, we identified the upstream regulator of Jab1/Csn5 expression and demonstrated its role in intrinsic resistance of NPC cells to treatment with cisplatin. Signal transducer and activator of transcription-3 (Stat3) expression correlates with and contributes to Jab1/Csn5 transcription. Consistently, silencing of Stat3 in tumors reduced Jab1/Csn5 expression, thereby sensitizing NPC cells to cisplatin-induced apoptosis both in vitro and in vivo. Mechanistically, Stat3 transcriptionally regulated Jab1/Csn5. Furthermore, high mRNA expression levels of Stat3 or Jab1 in colon cancer, breast cancer and glioblastoma are associated with significantly shorter survival times from the R2 online database. These findings identify a novel Stat3-Jab1/Csn5 signaling axis in cancer pathogenesis with therapeutic and prognostic relevance.

1 February 2014 in Human Pathology
Verified
Journal Article
Closed access
VLVasiliki Leventaki
Vasiliki Leventaki
JMJohn T. Manning
John T. Manning
RLRajayalakshmi Luthra
Rajayalakshmi Luthra
PMPramod Mehta
Pramod Mehta
YOYasuhiro Oki
Yasuhiro Oki
FVFrancisco Vega
Francisco Vega